Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The meeting was postponed until today. We should have heard something by now, I wander if they still did not get the desired votes.
Old Coach I am about 98% down for my original investment I've got no choice but to see what the final outcome will be. If and that is a very big if, one or two of those products in their pipeline would become successful it's not entirely out of the question that this could be a billion dollar company someday. Twenty percent ownership would make Apri worth 200 million and that would make me at least recoup a third of my investment. I am not counting on it, but I'm taking a chance on what little I have left.
It does not matter what the price per share is, Apri owns 14% of the company and whatever price shares of Seel opens on Nasdaq Apri will own 14 %. Whatever percentage we own of apricus will determine how many shares we own of the the new company.
Did he exercises warrants is that what happened. If so why would he do that now
I hope not! It is only 27% above previous close, that would be around $3.35 for us. I know you meant a pure $20 dollar bump. I am with you on that!
I guess anyway you look at it Denner needs at least 8 to $10 a share to break even. I would think that after all this time he would be looking to make a profit and not just break even.
Old Coach I have been in this investment for almost 10 years I originally bought it $5 a share . I believe that with FDA approval, Allergan marketing this product and good sales, this stock could see 15 to 20 dollar price. The sale and marketing of Rayva and the enhancement of the pipeline we could see >$25 share price. If the company gets sold after approval will be lucky to see $10 a share.
According to the Apricus website institutional, mutual funds, hedge funds and insiders make up around 50 % of the outstanding shares.
Any thoughts on why a mixed shelf was submitted if they have enough funds till the end of 2018.
Why would they have to do a capital raise if Vitaros gets approved and Allegran opts in for 25 million?
Sad to say, I am one of those who held and continues to hold. I had opportunities to bail, but greed or faith in a higher price to get even kept me in. Its all of nothing now.
There is no doubt that Sarrisa, Anson funds, or others are shorting this stock. They may be making some of their money back, but I have to believe they are betting on the U.S. approval of Vitaros to warrant their staying in this stock. As for myself, I need a 15 bagger to get even (ouch!), I don't know of any other stock that could do that in 18 months. I may be dreaming, but I believe that with a U.S. approval and sales within a year after that I may have a chance at getting even.
What I do not understand is why are they doing this if is not in the best interest of the company and the shareholders. The higher the pps the more money they make in options and in incentives. I don't believe that Denner invested in this company to not make money and Pascoe took the job for a quick buck and move on. I know what they done in hindsight does not make sense, but I have to believe they are trying to make this work. The market treated this company like a one trick pony with the failure of Fispemifene when the golden egg has always been Vitaros. The game is not over and I don't believe that Denner and Pascoe are out to ruin the shareholders and company at their expense.
The 1+ million coming from ex-U.S. sales would more than cover the payroll.
Oldtimerami, I beginning to think we would have been better off going ahead and being delisted and not had a reverse split. We would still have revenue from partners and who knows maybe the stock would have stabilized at around $.50 a share and after nda back over a $1.
Aprilov, I am with you !
If the price per share goes to $4.53 it will also meet the requirement with a 35 million dollar market cap
I know that management seems to be in apt at times however, I believe that all of these situations were addressed with the FDA meeting they had last year. The device situation was a surprise to management at that meeting ,so I'm sure if there were other issues they would have been brought up at that meeting. The purpose of that meeting last year was to make sure that all the i's are dotted and all the t's are crossed, we have to believe that management wants to get it right this time.
OldtimeramI, I also do not understand why they sold the ex-U.S. rights of Vataros. I listen to the conference call and Pascoe still mentions a substantial liability on the ex-U.S. Vataros. Whatever that liability was must have been the push for the sale. In 2010, I participated in a private placement which included warrants at an exercise price of $5.25 (ha-ha) they expired last month after 5 years. This makes the sale more harder to comprehend.
Old-timer, as an afterthought in the pr released by the company they mentioned a liability concern as one of the reasons for the sale. I wonder what liability they could have had if they would have kept ex- U.S. sales.
Eicoman, I must admit I am a little too much optimistic, but 150m in sales is only 5% of market share. The company predicted 200m on worldwide sales by 2020 which is @ 20-25% of market share. If the U.S. is half of the market a 150m sales objective would only be 5%. If that is all Vitaros is going to sell in the U.S. than I agree with 10-$12 pps. As far as Rayva is concerned 50m sales objective with no partner split is still good for $25> pps.
I invested in Apricus @ 2009, Dr. Bassam was at the helm of the company. Vitaros had not been approved and they did not have rights to the U.S. The stock traded at the $5 range pre-split, the hype was all about Vitaros ex-U.S. Rayva and Femprox were where they are now, just in the pipeline. Since then there has been many decision errors made by former and current management that have resulted in mistrust of the management capabilities of delivering on stated goals. The fact remains that U.S. approval of Vitaros is a real possibility and a 20% market share of a 3 billion market equals to 60 million revenue[600m x 10%] at 10% royalty from sales. That would be &7.75 revenue per share and at just 6x earnings equals $46.50 per share. The rayva market in the U.S. alone is at least 100 million and Apricus does not have to split that with any partners, $100 million revenue on 7,733,000 shares is $12.93 revenue per share at a very conservative estimate 6x revenue equals $77.58 per share. This is why I am still here and continue to buy on a regular basis. I may be the biggest fool on this board; however, there are at least a couple of other investors [Denner,Anson] that see potential as I see it. GLTA
There is no china or India Ferring has world less U.S.
I am a little perplexed in the ex-US market of about 3 billion being sold for 11.5 million. The milestones payments would be worth 10 times that not counting double digit royalties. I think the sale is good, it should have been for at least 25 million.
I have held my shares for over 5 years so holding for one more year is not a problem.
If it will make you feel any better, I bought more and my break-even is $34
Actually they have reduced their holdings by about 20%. According to the most recent 13G filing their holding is 4.9% at 394,482 shares. This is down from 509,258 post split shares.
Thanks for the explanation.
Oldtimer, thanks for your post. I am confused with the 2.5m stockholder equity requirement. I thought Apricus only needed the 35m market cap to continue listing, before then it was the PPS had to be $1 or greater.
A double from here to reach a market cap of 35 million is not exactly a miracle. An NDA submission, a few launches, more partners, Rayva news, or more Institutional investors could very well do it.
The value of the shares determines the market cap. The cash on hand has no bearing on the market cap. Granted if they had 35m in cash the pps would be higher imo.
When you add the insiders and Aspire the total is closer to 50%.
I'm going by what was said in the presentation.
On the conference call during the question and answer portion Pascoe indicated it may be sooner for the approval of Vitaros in the U.S. It all depends on the FDA and its meeting times. He also indicated there may be launches or approvals this month. The push for Vitaros as a first line of treatment sounds very promising. He said they are running at a burn rate of a 100k per month, not exactly a panic situation with 6m on hand.
That is only an average of $.17 a week for the next five months.
It is better to listen to the conference call. There was some things that were said that are not on the transcript that are good
Shaggy, what is your average cost per share?
Make it $34.50 so I can break even and you all make a profit.
I am confused , Vitaros doesn't do anything for the T levels . It has to do with blood flow at the source. How can Vitaros go after the low T market.
, why would that be better, if they offered 100% more than the current value that would only be $0.40 pre split. If that's the best we can hope for then why bother. If that's all I had to look forward to with this company I would have gotten out long time ago.